Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin | Zendy

Pragya D. Yadav | Zendy; Gajanan Sapkal | Zendy; Raches Ella | Zendy; Rima R. Sahay | Zendy; Dimpal A. Nyayanit | Zendy; Deepak Y. Patil | Zendy; Gururaj Deshpande | Zendy; Anita M. Shete | Zendy; Nivedita Gupta | Zendy; Viswanathan Mohan | Zendy; Priya Abraham | Zendy; Samiran Panda | Zendy; Balram Bhargava | Zendy

Open Access

Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin

Author(s) -

Pragya D. Yadav,

Gajanan Sapkal,

Raches Ella,

Rima R. Sahay,

Dimpal A. Nyayanit,

Deepak Y. Patil,

Gururaj Deshpande,

Anita M. Shete,

Nivedita Gupta,

Viswanathan Mohan,

Priya Abraham,

Samiran Panda,

Balram Bhargava

Publication year - 2021

Publication title -

journal of travel medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.985

H-Index - 59

eISSN - 1708-8305

pISSN - 1195-1982

DOI - 10.1093/jtm/taab104

Subject(s) - medicine , virology , covid-19 , neutralization , immunology , outbreak , virus , infectious disease (medical specialty) , disease , pathology

SARS-CoV-2 variant of concern mainly Delta and Beta is global public health concern due to its impact on existing vaccines. Here, we assessed the neutralization of sera from COVID-19 recovered cases and BBV152 vaccinees against Beta and Delta variants. BBV152 vaccine found to confer significant protection against both the variants.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research